[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
作者信息
Schnabel A, Gross W L
机构信息
Sana Rheumazentrum Baden-Württemberg, Klinik für Internistische Rheumatologie und Klinische Immunologie, Bad Wildbad.
出版信息
Dtsch Med Wochenschr. 2003 Jan 31;128(5):201-3. doi: 10.1055/s-2003-36975.
PMID:12557112
Abstract
摘要
相似文献
1
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
Dtsch Med Wochenschr. 2003 Jan 31;128(5):201-3. doi: 10.1055/s-2003-36975.
2
The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. doi: 10.1016/j.rdc.2004.01.005.
3
[Biological agents for therapy of rheumatoid arthritis--overview].
Nihon Rinsho. 2005 Jan;63 Suppl 1:513-6.
4
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Arthritis Rheum. 2004 Jan;50(1):277-90. doi: 10.1002/art.11487.
5
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
J Immunol. 1999 Aug 1;163(3):1521-8.
6
[When are "biologics" indicated?].
MMW Fortschr Med. 2006 Apr 27;148(17):10.
7
Molecular differences in anticytokine therapies.
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):241-8.
8
The 'alphabet' of rheumatoid arthritis treatment.
Medsurg Nurs. 2004 Dec;13(6):420-8.
9
Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
Ann Rheum Dis. 2005 Sep;64(9):1274-9. doi: 10.1136/ard.2004.031476. Epub 2005 Feb 11.
10
[Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Przegl Lek. 2002;59(11):916-8.
Zotero 插件